

# Prediction of medication response in children with Attention Deficit Hyperactivity Disorder (ADHD): Electroencephalogram (EEG) differences between responders and non-responders to methylphenidate

<b>Submission date</b> 16/07/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 16/07/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 27/10/2021	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr A.E. Wester

**Contact details**  
Utrecht Institute for Pharmaceutical Sciences  
Utrecht University  
Utrecht  
Netherlands  
3584 CA  
+31(0)30 253 7768  
A.E.Wester@uu.nl

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**Protocol serial number**

## Study information

### Scientific Title

Prediction of medication response in children with Attention Deficit Hyperactivity Disorder (ADHD): Electroencephalogram (EEG) differences between responders and non-responders to methylphenidate

### Study objectives

The EEG profile in responders to methylphenidate will be differ from the EEG profile in non-responders to methylphenidate (i.e., higher total power, increased theta/beta ratio and theta /alpha ratio).

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Ethics approval received from the local medical ethics committee

### Study design

Clinical trial

### Primary study design

Interventional

### Study type(s)

Not Specified

### Health condition(s) or problem(s) studied

Medication response in children with Attention Deficit Hyperactivity Disorder (ADHD)

### Interventions

Methylphenidate 10 mg.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Methylphenidate

### Primary outcome(s)

Primary outcome measure is the absolute and relative power in different frequency bands of the EEG.

### Key secondary outcome(s)

1. Event-related potentials in response to the stop-task and Continuous Performance Test (CPT)
2. EEG coherence
3. Scores on the Spatial Span (SSP) task and Spatial Working Memory (SWM) task from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
4. Gene polymorphisms of the dopamine D4 receptor (DRD4), dopamine transporter (DAT1), and serotonin transporter (5-HTT)
5. Scores on the 18-item Swanson, Nolan and Pelham Teacher and Parent Rating Scale (SNAP-IV)

**Completion date**

31/08/2007

## Eligibility

**Key inclusion criteria**

1. Diagnosed with ADHD combined type (no primary diagnoses of attention deficit) according to Diagnostic and Statistic Manual of mental disorders - fourth edition - criteria (DSM IV, APA 1994)
2. They have (no history of) anxiety disorder, depression, tics, psychosis or autism
3. Their age is ranged between 7 and 12
4. Intelligence Quotient (IQ) is above 75
5. They are free from psychoactive medication
6. They are free from methylphenidate at least 48 hours before testing
7. They have no known cardiovascular disease
8. Normal static binocular acuity, corrected or uncorrected
9. Written informed consent from the parents

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

7 years

**Upper age limit**

12 years

**Sex**

Not Specified

**Key exclusion criteria**

1. IQ is below 75
2. One or more of the following co-morbid disorders are diagnosed:
  - 2.1. Anxiety disorder
  - 2.2. Depression
  - 2.3. Tics

- 2.4. Psychosis
- 2.5. Autism
3. Prior enrolment in the same study
4. Participation in another clinical trial simultaneously
5. Familiar with epileptic disorders
6. Long term usage of methylphenidate (greater than three months)

**Date of first enrolment**

25/05/2007

**Date of final enrolment**

31/08/2007

## Locations

**Countries of recruitment**

Netherlands

**Study participating centre**

Utrecht Institute for Pharmaceutical Sciences

Utrecht

Netherlands

3584 CA

## Sponsor information

**Organisation**

Utrecht Institute for Pharmaceutical Sciences (The Netherlands)

**ROR**

<https://ror.org/04pp8hn57>

## Funder(s)

**Funder type**

Research organisation

**Funder Name**

Utrecht Institute for Pharmaceutical Sciences (The Netherlands)

# Results and Publications

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration